Equities

Camurus AB

Camurus AB

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (SEK)131.20
  • Today's Change2.20 / 1.71%
  • Shares traded121.11k
  • 1 Year change87.97%
  • Beta1.9232
Data delayed at least 15 minutes, as of Jun 03 2020 17:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.

  • Revenue in SEK (TTM)136.41m
  • Net income in SEK-283.79m
  • Incorporated--
  • Employees127.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Calliditas Therapeutics AB185.30m-53.74m3.72bn17.00--5.13--20.07-1.19-1.194.8918.720.2667--9.3213,235,930.00-7.74---8.25-------29.00------0.0032------75.33------
Oriola Oyj18.60bn117.80m3.97bn2.56k36.242.867.200.21360.05790.05799.830.73361.675.748.54633,073.101.072.813.759.0920.2421.510.6391.640.44694.380.643174.7010.891.32-25.93-29.67-6.14--
Orphazyme A/S0.00-471.89m4.05bn86.00--40.37-----16.87-16.870.002.65------0.00-------------------47.700.5836-------46.99------
Hansa Biopharma AB3.33m-380.90m5.32bn78.00--11.23--1,597.68-9.52-9.520.083311.840.0046--0.348445,027.03-52.99-38.19-57.02-41.5573.3585.18-11,431.57-4,954.36---164.280.0193--0.178715.76-45.18--23.28--
BioArctic AB254.82m78.39m5.67bn43.0085.896.9364.6422.260.89650.89652.8511.110.2074----6,067,024.006.38--7.38--88.25--30.76------0.0245---60.53---76.82------
Camurus AB136.41m-283.79m6.66bn127.00--11.68--48.83-5.73-5.732.7411.050.19031.055.801,136,725.00-39.59-34.29-48.18-42.7579.4292.92-208.05-200.022.51-235.640.044--114.12-12.70-23.52--29.19--
Oncopeptides AB0.00-903.96m8.05bn121.00--14.34-----16.75-16.750.009.130.00----0.00-125.14-109.07-148.75-137.31-----------1,068.000.00-------80.17------
Recipharm AB (publ)8.24bn33.40m8.71bn7.29k413.901.469.791.060.26380.2638102.8474.810.4412.504.661,199,156.000.17931.520.20251.7547.0048.070.40662.771.502.220.708234.2317.0023.75115.1816.4511.35--
AddLife AB3.69bn159.60m9.25bn1.00k59.576.0424.442.511.411.4132.7013.941.145.235.753,956,438.004.98--8.51--34.69--4.37--0.493213.330.4178--40.21--8.74------
Data as of Jun 03 2020. Currency figures normalised to Camurus AB's reporting currency: Swedish Krona SEK

Institutional shareholders

19.47%Per cent of shares held by top holders
HolderShares% Held
Max Mitteregger Kapitalf�rvaltning ABas of 30 Apr 20203.86m7.48%
Fj�rde AP-fondenas of 30 Apr 20203.33m6.45%
Catella Fondf�rvaltning ABas of 31 Dec 20191.06m2.05%
Enter Fonder ABas of 30 Apr 2020437.56k0.85%
Handelsbanken Fonder ABas of 31 Mar 2020404.95k0.78%
SEB Investment Management ABas of 30 Apr 2020347.87k0.67%
Lancelot Asset Management ABas of 30 Apr 2020328.00k0.64%
Andra AP-fondenas of 31 Dec 2019180.86k0.35%
BlackRock Fund Advisorsas of 07 May 202077.44k0.15%
Vanguard Investments Australia Ltd.as of 31 Mar 202023.76k0.05%
More ▼
Data from 31 Dec 2016 - 30 Apr 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.